Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Tislelizumab can cause cutaneous lupus erythematosus.

JAK inhibitors show promise in treating difficult skin diseases.

Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.

Radiesse is a versatile facial injectable used for cosmetic improvements and long-term collagen production, with careful dosing needed to prevent complications.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Ruxolitinib can help regrow hair in severe alopecia areata.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Topical ruxolitinib quickly improves non-segmental vitiligo.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.